Healthcare Focus AP LUSA specializes in supportive insights for pharmaceutical and life sciences leaders, presenting a ground to upsell advanced analytics, market access strategies, and real-world evidence services to pharmaceutical clients seeking impact on patient outcomes.

Executive Leadership A new CEO appointed in December 2024 signals potential strategic pivots and expanded client engagement opportunities. Leverage this leadership change to position strategic growth projects, advisory services, and premium research collaborations.

Real World Evidence Recent activity includes real-world evidence posters and immunology oncology work, indicating a strong footing in RWE offerings. Target pharma brands investing in post-marketing insights, payer value dossiers, and outcomes-based pricing discussions.

Syndicated Studies Launch of syndicated RSV vaccination study demonstrates appetite for collaborative, multi-client research. Offer co-funded studies, partner-integrated study designs, and expansion into adjacent vaccine or immunology areas to accelerate partnerships.

Growth Readiness Revenue range places APLUSA in a mid-market segment with 201-500 employees, suggesting openness to scalable services, tiered pricing, and long-term retainer models for ongoing analytics, digital listening, and AI-enabled insights.